1-7 of 7
Steven R. Schuster
Close
Sort by
Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early-Stage Classical Hodgkin Lymphoma (SGN35-027 Part C)

Jeremy S. Abramson, David J. Straus, Nancy L. Bartlett, John M. Burke, Ryan C Lynch, Eva Domingo Domenech, Brian Hess, Steven R. Schuster, Yuliya Linhares, Rod Ramchandren, Mitul Gandhi, Rex Mowat, Harsh Shah, Wojciech Jurczak, Alessandro Re, Uwe Hahn, H. Miles Prince, Wenchuan Guo, Linda Ho, Rose C. Beck, Christopher A. Yasenchak, Hun Ju Lee
Journal: Blood
Blood (2023) 142 (Supplement 1): 611.
https://doi.org/10.1182/blood-2023-172574
Published: 2023
Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)

Hun Ju Lee, Jeremy S. Abramson, Nancy L. Bartlett, John M. Burke, Ryan C. Lynch, Domingo Domenech Eva, Brian T. Hess, Steven R. Schuster, Yuliya Linhares, Rod Ramchandren, Mitul Gandhi, Rex Mowat, Harsh Shah, Giuseppe Rossi, Uwe H Hahn, Henry Miles Prince, Linda Ho, Wenchuan Guo, Christopher A. Yasenchak, David J. Straus
Journal: Blood
Blood (2022) 140 (Supplement 1): 9399–9401.
https://doi.org/10.1182/blood-2022-156576
Published: 2022
Journal Articles

Cereblon Expression Predicts Response, Progression Free and Overall Survival After Pomalidomide and Dexamethasone Therapy in Multiple Myeloma

Steven R. Schuster, MD, Klaus Martin Kortuem, MD, Yuan Xiao Zhu, PhD, Esteban Braggio, Ph.D., Chang-Xin Shi, PhD, Laura Bruins, Jessica Schmidt, Gregory Ahmann, BS, Shaji K. Kumar, MD, S. Vincent Rajkumar, Joseph R. Mikhael, MD, Vivek Roy, M.D., Betsy R. LaPlant, Kristina Laumann, Bart Barlogie, MD, John D Shaughnessy, Jr., PhD, Rafael Fonseca, MD, Leif Bergsagel, MD, Martha Q Lacy, MD, Keith Stewart, MD
Journal: Blood
Blood (2012) 120 (21): 194.
https://doi.org/10.1182/blood.V120.21.194.194
Published: 2012
Journal Articles

Activity of Single Agent Drugs in Phase I and II Trials Best Predicts Future Clinical Utility in Multiple Myeloma

Klaus Martin Kortuem, MD, Steven R Schuster, MD, Meaghan L. Khan, MD, Kaitlyn E. Zidich, Victor H Jimenez-Zepeda, MD, Rafael Fonseca, MD, Keith Stewart, MBA, MB, CHB
Journal: Blood
Blood (2012) 120 (21): 4034.
https://doi.org/10.1182/blood.V120.21.4034.4034
Published: 2012
Journal Articles

Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis

Brief Report
Joseph R. Mikhael, Steven R. Schuster, Victor H. Jimenez-Zepeda, Nancy Bello, Jacy Spong, Craig B. Reeder, A. Keith Stewart, P. Leif Bergsagel, Rafael Fonseca
Journal: Blood
Blood (2012) 119 (19): 4391–4394.
https://doi.org/10.1182/blood-2011-11-390930
Published: 2012
Journal Articles

Cereblon Expression Is Required for the Anti-Myeloma Activity of Lenalidomide and Pomalidomide

Yuan Xiao Zhu, PhD, Esteban Braggio, PhD, Chang-Xin Shi, PhD, Jessica Schmidt, Laura Bruins, Steven R. Schuster, MD, Rafael Fonseca, MD, P. Leif Bergsagel, MD, Chad C. Bjorklund, Ph.D., Robert Z. Orlowski, MD, PhD, A. Keith Stewart, MD
Journal: Blood
Blood (2011) 118 (21): 127.
https://doi.org/10.1182/blood.V118.21.127.127
Published: 2011
Journal Articles

The Combination of Cyclophosphamide-Bortezomib-Dexamethasone (CYBOR-D) Is a Highly Effective and Well Tolerated Regimen that Produces Rapid and Complete Hematological Response In Patients with AL Amyloidosis

Joseph R. Mikhael, MD, Steven R. Schuster, MD, Victor H Jimenez-Zepeda, MD, PD, Nancy Bello, Jacy Spong, Craig B. Reeder, MD, A. Keith Stewart, MD, P.Leif Bergsagel, MD, Rafael Fonseca
Journal: Blood
Blood (2010) 116 (21): 3063.
https://doi.org/10.1182/blood.V116.21.3063.3063
Published: 2010